Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), American Well (AMWL) and Avita Medical (RCEL)
Analysts fell to the sidelines weighing in on Dexcom (DXCM – Research Report), American Well (AMWL – Research Report) and Avita Medical (RCEL – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dexcom (DXCM)
In a report released today, Suraj Kalia from Oppenheimer reiterated a Hold rating on Dexcom. The company’s shares closed last Thursday at $65.08, close to its 52-week low of $62.34.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of
Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $84.19, a 23.8% upside from current levels. In a report issued on January 30, TipRanks – xAI also downgraded the stock to Hold with a $80.00 price target.
See today’s best-performing stocks on TipRanks >>
American Well (AMWL)
Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on American Well today and set a price target of $6.00. The company’s shares closed last Thursday at $4.33.
According to TipRanks.com, Hettenbach is ranked #4047 out of 12109 analysts.
Currently, the analyst consensus on American Well is a Hold with an average price target of $5.33, which is a 22.0% upside from current levels. In a report released yesterday, BTIG also maintained a Hold rating on the stock.
Avita Medical (RCEL)
Lake Street analyst Frank Takkinen maintained a Hold rating on Avita Medical today and set a price target of $3.50. The company’s shares closed last Thursday at $3.72.
According to TipRanks.com, Takkinen is a 1-star analyst with an average return of
Currently, the analyst consensus on Avita Medical is a Moderate Buy with an average price target of $4.50, representing a 17.2% upside. In a report released today, TipRanks – PerPlexity also upgraded the stock to Hold with a $4.00 price target.
